Despite the morbidity associated with coronary artery bypass graft, this procedure has never been entirely displaced by percutaneous coronary intervention. The results from the latest in a series of studies does not seem to help the case for drug-eluting stents (DES) for patients with three-vessel disease, as the data from this study failed to demonstrate non-inferiority for DES devices implanted with the help of fractional flow reserve measurement to ensure optimal stent placement.
Plants could be an alternative vaccine platform for both COVID-19 and future pandemics, shaking up a biologics sector that is currently mostly protein-based. South Korean company Bioapplications Inc., for example, is aiming to have a plant-derived booster shot for COVID-19 in the clinic in 2022.
PERTH, Australia – Investment in regenerative medicine in Australia in 2020 was AU$394.1 million (US295.8 million), accounting for nearly 23% of the overall capital invested in the Australian biotech sector, according to a new report published by Australia’s Regenerative Medicine Consortium.
A brighter future awaits radiotherapy if Flash and LIGHT live up to their promise. Announcements made last week by Varian Medical Systems and Advanced Oncotherapy plc indicate results should be seen soon. Varian reported that the first human clinical trial of Flash, Fast-01, completed its treatment phase last week at the Cincinnati Children’s/University of Cincinnati Health Proton Therapy Center. Advanced Oncotherapy plc presented results from a modeling study of Linac for Image Guided Hadron Therapy (LIGHT) technology at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting demonstrating that LIGHT enables both the high, super-quick dose delivery of Flash and good conformality of dose delivery to tumor tissue.
RSS
